Swiss 3RCC’s Post

Are you pioneering advanced #InVitro models like organoids or organ-on-chip? Or maybe integrating #InSilico methods, such as computational modeling, into your research? 𝗛𝗼𝘄 𝘄𝗶𝗱𝗲𝗹𝘆 𝘁𝗵𝗲𝘀𝗲 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀 𝗮𝗿𝗲 𝗰𝘂𝗿𝗿𝗲𝗻𝘁𝗹𝘆 𝘂𝘀𝗲𝗱 𝗶𝗻 𝗰𝗹𝗶𝗻𝗶𝗰𝘀 𝗮𝗻𝗱 𝗱𝗿𝘂𝗴 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁? 📅 Join us at our symposium co-organized with the Federal Food Safety and Veterinary Office FSVO, "Successfully Implementing NAMs" on December 13th to find out more! This event offers a unique platform to explore the implementation of New Approach Methodologies. Connect with developers, end-users, and regulatory bodies to learn practical steps for streamlining adoption. Gain insights from case studies presented by experts in the clinical and pharmaceutical sectors, revealing the critical steps to turn innovation into impactful applications. 👉 Don’t miss this opportunity to set your non-animal methods up for success by mastering essential considerations in development. Register now: https://buff.ly/4gWot5a #NAMs #Replacement

🧠 How is AI revolutionizing pricing in the pharmaceutical industry? 📊 What makes data the new gold standard for pricing strategies? 🌍 Which innovative models are transforming the life sciences sector? 🐾 How can we unlock unprecedented revenue growth in animal health? 💡 Can value-based strategies truly drive sustainable success in today’s market?   These are just a few of the burning questions we'll explore at the EPP Life Sciences Pricing Forum 2024!    Dive deep into these groundbreaking topics and uncover the future of pricing in life sciences. Get all the insights and details by downloading the brochure now:  https://lnkd.in/d6QqurNj #EPP #EPPLSPF #LSF24 #LifeSciences #Biopharma #PricingStrategies #Innovation #Healthcare #LifeSciences2024

In vitro biocompatibility testing can help identify potential safety hazards during the earliest stages of product development, without animal testing. https://lnkd.in/dKDgxMrx #productsafety #biocompatibility #productdevelopment #researchanddevelopment #medicaldevice #consumerproducts #rawmaterials #invitro #ISO10993

The FDA continues to push for reducing and eliminating #animaltesting to advance the development of human therapies. Although animal models have played a crucial role in establishing therapies, there are limitations in translating these therapies to humans. Humabiologics supports this effort by offering #researchers human derived #biomaterials that are more clinically relevant to developing #invitro models that predict #toxicity levels better than animal models. Learn more about Humabiologics products here: https://lnkd.in/e-pi48RE To learn more about the advocacy groups push for non-animal methods to predict the safety of drugs: https://lnkd.in/dNPdyQDH #regenerativemedicine #tissueengineering #collagen

INVESTIGATION High throughput screening (HTS) is the use of automated equipment to rapidly test thousands to millions of samples for biological activity at the model organism, cellular, pathway, or molecular level. IT IS WIDELY USED AND HAS BEEN FOR OVER 15 YEARS. It is proprietary in use. What does that mean? It means that individual companies ( LIKE CHARLES RIVER AND LABCORP), multinationals ( LIKE JOHNSON & JOHNSON) are building their own libraries ( databases ) of millions of chemical compounds. MANY WERE STARTED OVER A DECADE AND HALF AGO. What should be happening is that these libraries should be catalogued and sent to the regulators who tell anyone who wants to test using animals to go back and pay the licence fee to use these proprietary libraries as they replace animals. NO CHOICE> This should be compulsory as many nations are literally decades behind and would benefit from this. The companies making these get a licence fee which is fair. THE REGULATORS ARE NOT DOING THEIR JOB. THE PRIORITY IS HUMAN AND ANIMAL HEALTH NOT PROPPING UP PROFITS. TAXPAYERS ARE PAYING FOR THIS WASTE. #highthoughputscreening #animaltesting https://lnkd.in/ecz855Wu

How can AI help us to become less dependent on animal testing? Our colleague Marc Teunis explains this to Proefdiervrij in their recent article! At Hogeschool Utrecht, Marc is developing AI tools to predict substance safety, reducing the reliance on animal models. His work not only enhances ethical research but also improves accuracy in toxicology. Next to this, Marc is involved in educating future professionals on the application of AI in this field, contributing to the shift towards animal-free testing. Read more about Marc's work in the article: https://lnkd.in/ek6m8GP3 #VHP4Safety #AnimalFreeResearch #AIinScience #Innovation

I am happy to share the below post from the European Society of Toxicology in Vitro (ESTIV), which mentions ReadyCell and other new partners. We have officially joined ESTIV! 🎉 We believe in advancing science responsibly and ethically. By joining forces with ESTIV, we want to raise awareness and advocate for the widespread adoption of innovative, cruelty-free methods and non-animal alternatives in toxicology research. #ReadyCell #ESTIV #InVitroToxicology #Research #EthicalScience #AnimalWelfare #Sustainability #ScienceAdvocacy 🌱🔬

Enhance your food testing with access to technical content and resources to help ensure safety standards. Comply with regulations for trace-level detection of pesticides, toxins, and veterinary drugs. Elevate your laboratory performance with our one stop shop now ⬇️⬇️⬇️ #FoodSafety #FoodTesting #FoodAnalysis #AllergenTesting #PesticideTesting #FoodAuthenticityTesting

✨ Currently, the mini osmotic pump has successfully assisted over 500 clients in conducting their experiments smoothly. The mini osmotic pump has become the best tool for continuous doses of unrestrained laboratory animals. It can be implanted subcutaneously or intraperitoneally in animals. Minimizes side effects and experimental variables and reduces the risk of stress due to frequent animal handling. It is used for continuous delivery of a wide range of drugs, including antibodies, growth factors, cytokines, chemotherapeutics, addictive drugs, hormones, steroids and more. 📌 Check out the document below for more information, and feel free to message us!

⏳ Prolonging drug half-life through ISOXTEND® VHH antibodies, or nanobodies, are powerful biological products with low production costs. However, they face a key challenge: short half-life in the bloodstream due to their small size. Isogenica, has developed ISOXTEND® to overcome this limitation. This technology extends the half-life of VHHs, broadening their therapeutic applications. 🐕 But there’s something even more exciting: #ISOXTEND® isn’t limited to human therapeutics. Thanks to its versatility, it’s been shown to work effectively across various animal species. Not only is this great news for pre-clinical development, but it also opens the door to innovations in veterinary medicine. Whether for companion animals like dogs or agricultural animals like cows, ISOXTEND® offers great potential for human and animal health. 🔍 Explore the full details in our poster: https://loom.ly/Drlv0Yw #VHH #Therapeutics #AnimalHealth #Preclinical